Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9539
-0.0761-7.39%
Volume:4.88M
Turnover:4.77M
Market Cap:264.33M
PE:-8.58
High:1.05
Open:1.03
Low:0.9500
Close:1.03
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:0.55
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:10.57
PE(LYR):-45.90

Loading ...

Akebia Therapeutics Initiated at Buy by WestPark Capital

Dow Jones
·
Sep 08

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

Akebia Grants New Hire Stock Options for 8,400 Shares at $0.92 Each

Reuters
·
Sep 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 02

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

GlobeNewswire
·
Sep 01

Akebia Therapeutics Cut to Market Perform from Outperform by Leerink Partners

Dow Jones
·
Aug 08

Akebia downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Aug 07

Akebia Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Akebia Q2 FY26 Turns to Net Loss of $8.9 Million; Revenue Falls 21.44% to $49.1 Million

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate

Benzinga Earnings
·
Aug 06

Akebia Therapeutics Inc Expected to Post a Loss of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Akebia Grants 2 New Hires Options for 61,000 Shares at $1.32 Each

Reuters
·
Aug 04

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Akebia Initiates Phase 2 Basket Trial of Complement Inhibitor Ebribafusp in Rare Kidney Diseases

Reuters
·
Aug 03

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

THOMSON REUTERS
·
Aug 03

Akebia Therapeutics Schedules Quarterly Results Release, Conference Call

Reuters
·
Jul 29

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
Jul 29

Monopar Adds Ex-kalvista CCO Nicole Sweeny to Board

Reuters
·
Jul 20

Akebia Grants 125,600 Inducement Stock Options to New Hires at USD 1.14 a Share

Reuters
·
Jul 03